ATE448232T1 - Substituierte heterozyklen - Google Patents

Substituierte heterozyklen

Info

Publication number
ATE448232T1
ATE448232T1 AT04708731T AT04708731T ATE448232T1 AT E448232 T1 ATE448232 T1 AT E448232T1 AT 04708731 T AT04708731 T AT 04708731T AT 04708731 T AT04708731 T AT 04708731T AT E448232 T1 ATE448232 T1 AT E448232T1
Authority
AT
Austria
Prior art keywords
substituted heterocycles
heterocycles
substituted
medicaments
asthma
Prior art date
Application number
AT04708731T
Other languages
German (de)
English (en)
Inventor
Marc Stadler
Stephan Seip
Hartwig Mueller
Anke Mayer-Bartschmid
Michael-Alexander Bruening
Jordi Benet-Buchholz
Hiroko Togame
Reiko Dodo
Peter Reinemer
Kevin Bacon
Kinji Fuchikami
Satoko Matsukawa
Klaus Urbahns
Original Assignee
Intermed Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermed Discovery Gmbh filed Critical Intermed Discovery Gmbh
Application granted granted Critical
Publication of ATE448232T1 publication Critical patent/ATE448232T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT04708731T 2003-02-14 2004-02-06 Substituierte heterozyklen ATE448232T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03003495 2003-02-14
EP03007594 2003-04-02
PCT/EP2004/001097 WO2004071382A2 (en) 2003-02-14 2004-02-06 Substituted heterocycles

Publications (1)

Publication Number Publication Date
ATE448232T1 true ATE448232T1 (de) 2009-11-15

Family

ID=32870763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04708731T ATE448232T1 (de) 2003-02-14 2004-02-06 Substituierte heterozyklen

Country Status (15)

Country Link
US (2) US20060229353A1 (en:Method)
EP (1) EP1597262B1 (en:Method)
JP (1) JP4795931B2 (en:Method)
KR (1) KR20050098928A (en:Method)
CN (1) CN1845925B (en:Method)
AT (1) ATE448232T1 (en:Method)
AU (1) AU2004212296B2 (en:Method)
BR (1) BRPI0407234A (en:Method)
CA (1) CA2515940C (en:Method)
DE (1) DE602004024037D1 (en:Method)
ES (1) ES2336562T3 (en:Method)
IL (1) IL169897A0 (en:Method)
IN (1) IN228043B (en:Method)
MX (1) MX272108B (en:Method)
WO (1) WO2004071382A2 (en:Method)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341414B1 (en) 2000-11-16 2013-01-02 The Regents of The University of California Marine actinomycete taxon for drug and fermentation product discovery
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
PL2441767T3 (pl) * 2003-06-20 2015-11-30 Univ California Salinosporamidy i sposoby ich stosowania
AU2004253478A1 (en) 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
JP2007535559A (ja) * 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド [3.2.0]複素環式化合物及びその使用法
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
KR20070041742A (ko) * 2004-07-12 2007-04-19 바이엘 크롭사이언스 아게 살진균제 및 살충제로서의 치환된 2-피롤리돈 유도체
MX2007006526A (es) * 2004-12-03 2007-09-19 Dana Farber Cancer Inst Inc Composiciones y metodos para tratamiento de enfermedades neoplasicas.
AU2005311572A1 (en) * 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using (3.2.0) heterocyclic compounds and analogs thereof
WO2006118973A2 (en) * 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
MX2008012847A (es) 2006-04-06 2008-10-13 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y analogos de la misma.
WO2008095195A2 (en) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
NZ587985A (en) 2008-03-07 2012-07-27 Nereus Pharmaceuticals Inc Total synthesis of salinosporamide a and analogs thereof
EP2276765A4 (en) 2008-05-12 2011-10-19 Nereus Pharmaceuticals Inc SALINOSPORAMIDE DERIVATIVES AS PROTEASOMAL HEMMER
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
JP6251176B2 (ja) 2011-10-28 2017-12-20 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nae阻害物質に対する応答のバイオマーカー
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3339291A1 (en) 2016-12-22 2018-06-27 Vita Api Proteasome inhibiting ss-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
EP1341414B1 (en) * 2000-11-16 2013-01-02 The Regents of The University of California Marine actinomycete taxon for drug and fermentation product discovery

Also Published As

Publication number Publication date
JP4795931B2 (ja) 2011-10-19
WO2004071382A2 (en) 2004-08-26
DE602004024037D1 (de) 2009-12-24
CN1845925B (zh) 2010-11-03
IN2005DE03350A (en:Method) 2007-06-01
WO2004071382A3 (en) 2005-01-06
EP1597262A2 (en) 2005-11-23
IN228043B (en:Method) 2009-02-13
US20110015248A1 (en) 2011-01-20
CN1845925A (zh) 2006-10-11
IL169897A0 (en) 2007-07-04
US20060229353A1 (en) 2006-10-12
AU2004212296A1 (en) 2004-08-26
KR20050098928A (ko) 2005-10-12
HK1096392A1 (en) 2007-06-01
EP1597262B1 (en) 2009-11-11
MX272108B (es) 2009-11-25
MXPA05008478A (es) 2005-10-18
CA2515940A1 (en) 2004-08-26
BRPI0407234A (pt) 2006-01-31
ES2336562T3 (es) 2010-04-14
JP2006517934A (ja) 2006-08-03
CA2515940C (en) 2011-12-06
AU2004212296B2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
ATE448232T1 (de) Substituierte heterozyklen
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
UA85559C2 (en) Aminobenzophenone compounds
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
ATE408601T1 (de) Fredericamycin-derivate
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE453642T1 (de) Substituierte phenylaminopyrimidine
IL209879A0 (en) Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
SE0302304D0 (sv) Novel compounds
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE524488T1 (de) Lysobactinamide
SE0300457D0 (sv) Novel compounds
ATE380188T1 (de) Substituierte chinolone
TW200504051A (en) Novel acridine derivatives and their use as medicaments
ATE433459T1 (de) Desoxo-nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties